• AKT inhibitor
• capivasertib based treatment
• capivasertib plus paclitaxel
• ipatasertib based treatment
• ipatasertib plus paclitaxel
• cyclin inhibitor
• abemaciclib based treatment
• abemaciclib plus aromatase inhibitor
• abemaciclib plus endocrine therapy
• palbociclib based treatment
• palbociclib plus endocrine therapy
• palbociclib plus letrozole
• ribociclib based treatment
• ribociclib plus letrozole
• HER inhibitor
• HER2 inhibitor
• trastuzumab based treatment
• trastuzumab plus endocrine therapy
• TKI anti HER1/EGFR and HER2/neu
• lapatinib based treatment
• lapatinib plus fulvestrant
• lapatinib plus letrozole
• IGF-1R inhibitors
• dalotuzumab plus ridaforolimus plus exemestane
• VEGF(R) inhibitor
• cediranib plus fulvestrant

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs taxanes
• vs paclitaxel
• vs endocrine therapy
• vs aromatase inhibitor
• vs exemestane
• vs exemestane plus ridaforolimus
• vs fulvestrant
• vs letrozole
• vs HER inhibitor
• vs HER2 inhibitor
• vs trastuzumab based treatment
• vs trastuzumab plus chemotherapy

  Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

color = results color = ROB demonstrated suggested inconclusive safety concern ongoing study not assessable low moderate serious ongoing study display ongoing demontrated benefit only